Physician profile
Michael Dirk Ory
NPI 1962410597
$1,323.08
in general payments reported to CMS, 2019-2025
21 companies · $69.28 in 2025
The $69.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $149 · 2021: $429 · 2022: $206 · 2023: $149 · 2024: $86.49 · 2025: $69.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.18 | 2020-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.03 | 2021-2025 | |
| Abbvie INC. | $109.33 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $108.18 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.71 | 2019-2023 | Jardiance |
| Amgen INC. | $91.96 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $54.15 | 2021-2025 | Arexvy, Shingrix |
| Pfizer INC. | $48.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.55 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $39.25 | 2023-2024 | Rexulti |
| Allergan, INC. | $38.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.17 | 2023 | Dificid |
| Exact Sciences Corporation | $31.64 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $27.69 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $27.67 | 2022 | |
| Boston Scientific Corporation | $18.83 | 2019 | |
| Vifor Pharma, INC. | $17.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.72 | 2022 | |
| Sun Pharmaceutical Industries INC. | $11.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.